What is SNOA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SNOA?

P/E (TTM) is n/a and 52-week range is $0.85 to $4.01 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SNOA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SNOA?

The company profile lists revenue (TTM) near $27M, net income (TTM) near -$282M, EPS (TTM) near -$1.22 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Sonoma Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boulder, Colorado, US, 4.8M shares outstanding, ISIN US83558L3033 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Sonoma Pharmaceuticals Inc

$SNOA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 260 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Employees

Website

sonomapharma.com

IPO

2007-01-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US83558L3033

Headquarters

Boulder, Colorado, US

Shares outstanding

4.8M

NAICS sector

Manufacturing

Institutional ownership

2.31%

Browse other companiesFree AI scores and summaries for more stocks